(Philadelphia, PA) - OncoLink, the University of Pennsylvania Cancer Center's award-winning web site, and EmergingMed are pleased to announce the launch of a new Clinical Trial Match & Referral Service. Available free to visitors of OncoLink.com, this service is the first phase of a three-year exclusive collaboration between Penn's Cancer Center and EmergingMed.com. It enables visitors to learn about clinical trials available through the University of Pennsylvania Cancer Center and to easily identify trials for which they or a loved one might be eligible.

One of the largest cancer information web sites and cited as one of the best internet sources of medical information by the Journal of the American Medical Association (JAMA - May 24, 2001), OncoLink recently underwent a dramatic expansion and re-design. The updated graphics and layout introduce improved navigation features to better accommodate the over 11.2 million visits from patients, families and providers who access the site monthly.

"We at EmergingMed and OncoLink share a steadfast commitment to improving patient access to cancer clinical trials and accelerating the process of finding better cancer treatments," said Courtney Hudson, chief executive officer and founder of EmergingMed.

"Through this collaboration we can further empower patients with easy to locate treatment options they might otherwise never know about," added James Metz, MD, assistant professor of Radiation Oncology at Penn and editor-in-chief of OncoLink. "At the same time, we've streamlined the process of getting eligible patients into clinical trials, making the experience as easy and convenient as possible"

Patients access the Clinical Trial Match & Referral Service at http://www.oncolink.com
under "Treatment Options" and "Clinical Trials." From there, visitors can either view a listing of available trials by cancer type or they can fill out a simple on-line questionnaire to determine their eligibility. All submitted information is kept strictly confidential. Within seconds, a response will show if a patient's profile matches the enrollment criteria for any clinical trials at the University of Pennsylvania Cancer Center. If a match is made with one or more clinical trials, an EmergingMed customer service specialist-upon request-will help facilitate contact with the team conducting the trials.

The service strives to respond to requests by phone the same day an application is submitted and within 48 hours for e-mail requests.

Additional support for the Clinical Trials Match and Referral Service has been provided by Aventis Pharmaceuticals.

OncoLink was founded in 1994 by Penn cancer specialists who wanted to help cancer patients, families, health care professionals and the general public get accurate, timely cancer-related information-quickly and free of charge. Through it, you can get information about specific types of cancer, news about research advances and updates on cancer treatment. OncoLink, which is managed and written by physicians and nurses of the University of Pennsylvania Cancer Center, has been recognized as one of the leading health resources on the Web, reaching over 11 million hits per month. It's received numerous awards including the coveted Global Information Infrastructure Award in 1998.

EmergingMed was founded in January 2000 to offer cancer patients and their families a fast and easy way to find and understand available treatment options and to speed up drug development through increased enrollment in clinical trials. The Company's clients include Aventis Pharmaceuticals, Genentech, SuperGen, Clinical Research Group, ILEX Oncology, Protein Design Labs, Antigenics, and the University of Arizona Cancer Center. Based in New York City, EmergingMed is a private health services and hosted application provider. For more information, call 212-594-7990 or write to ContactUs@emergingmed.com.


# # #


Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.

Share This Page: